Latest Institute of Cancer Research Stories
Cancer drug developer Antisoma, The Institute of Cancer Research and Cancer Research Technology have announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialize novel anticancer compounds called protein phosphatase magnesium-dependent 1 d inhibitors.
Cancer drug developer Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) today announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialise novel anti-cancer compounds called PPM1D (protein phosphatase magnesium-dependent 1 d) inhibitors.
By Nina Lakhani As money floods in for breast cancer and leukaemia research, 80 per cent of people with lung tumours are dying within a year of diagnosis Patients suffering from "unfashionable" cancers are being neglected by scientists in spite of record spending on cancer research, according to a new report by the National Cancer Research Institute (NCRI).
SCIENTISTS are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years. Abiraterone could treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they said.
By Phil Skelton Health reporter Prostate cancer patients in Gloucestershire have welcomed news of a new drug to treat an aggressive form of the disease. Abiraterone has been developed to fight prostate cancer, which kills 9,000 men in England and Wales every year, according to the NHS.
The Phase 1 clinical trial of the drug abiraterone revealed significant tumor shrinkage in men with advanced prostate cancer, researchers in Britain said.
MEN who expect to die from prostate cancer have been offered new hope by a drug which could represent the biggest step forward in treating the disease in 60 years. A preliminary trial has shown that abiraterone can reverse even the most aggressive, resistant and deadly cancers.
By Lyndsay Moss THE last decade has seen major leaps forward in cancer treatment in the search for the latest "wonder drug". Developments such as the creation of drugs which target particular types of cancer have brought new hope to patients.
By Lyndsay Moss THOUSANDS of men with prostate cancer could be helped by an "exciting" new drug which potentially represents the biggest step forward in treating the disease for 60 years, researchers revealed yesterday.
A WONDER pill blocks the advance of prostate cancer with hardly any side effects, it is claimed. Experts believe Abiraterone could treat eight out of 10 aggressive tumours that have resisted all other treatments.
- The parings of haberdine; also, any kind of fragments.